

Title: Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 study

Authors:

Beatriz Joven¹, Concepción Fito Manteca², Esteban Rubio³, Enrique Raya⁴, Alba Pérez⁵, Raquel Hernández⁶, Sara Manrique⁷, Mercedes Núñez⁸, Silvia Díaz-Cerezo⁸, Sebastián Moyano⁸, Alessandra Lacetera⁹, Rosario García-Vicuña¹⁰

¹ Rheumatology Department, Hospital 12 de Octubre, Madrid, Spain

² Rheumatology Department, Complejo Hospitalario de Navarra, Pamplona, Spain

³ Rheumatology Department, Hospital Virgen del Rocío, Sevilla, Spain

⁴ Rheumatology Department, Hospital Universitario Clínico San Cecilio de Granada, Granada, Spain

⁵ Rheumatology and Traumatology Department Hospital Puerta del Mar, Cádiz, Spain

⁶ Rheumatology Department, Hospital Universitario de Valme, Sevilla, Spain

⁷ Rheumatology Department, Hospital Carlos Haya, Málaga, Spain

⁸ Medical Department, Eli Lilly and Company, Alcobendas, Spain

⁹ OXON Epidemiology, Madrid, Spain

¹⁰ Hospital Universitario de la Princesa, ISS-Princesa, Madrid, Spain

Corresponding author:

Silvia Díaz-Cerezo

Email: diaz_silvia@lilly.com

SUPPLEMENTARY MATERIAL

Table 1- Comorbidities at baseline

	Overall	SECU150	SECU300	IXE
Patient – n (%)	221 (100.0)	103 (100.0)	38 (100.0)	80 (100.0)
- Cardiovascular diseases	68 (37.2)	38 (46.3)	8 (26.7)	22 (31.0)
- Obesity	56 (30.6)	20 (24.4)	15 (50.0)	21 (29.6)
- Liver disease	23 (12.6)	11 (13.4)	5 (16.7)	7 (9.9)
- Diabetes mellitus	22 (12.0)	8 (9.8)	1 (3.3)	13 (18.3)
- Other rheumatic diseases	21 (11.5)	11 (13.4)	3 (10.0)	7 (9.9)
- Depression	20 (10.9)	12 (14.6)	3 (10.0)	5 (7.0)
- Anxiety	16 (8.7)	9 (11.0)	1 (3.3)	6 (8.5)
- Fibromyalgia	15 (8.2)	8 (9.8)	2 (6.7)	5 (7.0)
- Osteoporosis	14 (7.7)	6 (7.3)	2 (6.7)	6 (8.5)
- Autoimmune ophthalmic disease	7 (3.8)	4 (4.9)	0 (0.0)	3 (4.2)
- Malignant tumor/s	7 (3.8)	4 (4.9)	1 (3.3)	2 (2.8)
- Inflammatory bowel disease	3 (1.6)	3 (3.7)	0 (0.0)	0 (0.0)
- Other*	95 (51.9)	44 (53.7)	16 (53.3)	35 (49.3)
- Dyslipidemia	12 (5.4)	3 (2.9)	4 (10.5)	5 (6.3)

*Only other comorbidities/conditions with a frequency of >5% have been listed

SECU150: Secukinumab 150mg, SECU300: Secukinumab 300mg, IXE: Ixekizumab.


Table 2 – Previous PsA treatments (only combination)

	Overall	SECU150	SECU300	IXE
Patients – n (%)	221 (100.0)	103 (100.0)	38 (100.0)	80 (100.0)
Treatment in patients with bDMARD as first agent – n (%)				
Adalimumab	60 (37.3)	22 (36.7)	10 (38.5)	28 (37.3)
- Combination	26 (16.1)	11 (18.3)	2 (7.7)	13 (17.3)
Adalimumab + Methotrexate	21 (13.0)	9 (15.0)	1 (3.8)	11 (14.7)
Adalimumab + Leflunomide	3 (1.9)	0 (0.0)	1 (3.8)	2 (2.7)
Adalimumab + Hydroxychloroquine (or Chloroquine)	1 (0.6)	1 (1.7)	0 (0.0)	0 (0.0)
Adalimumab + Sulfasalazine	1 (0.6)	1 (1.7)	0 (0.0)	0 (0.0)
Etanercept	49 (30.4)	17 (28.3)	8 (30.8)	24 (32.0)
- Combination	31 (19.3)	11 (18.3)	6 (23.1)	14 (18.7)
Etanercept + Methotrexate	23 (14.3)	8 (13.3)	4 (15.4)	11 (14.7)
Etanercept + Leflunomide	6 (3.7)	2 (3.3)	2 (7.7)	2 (2.7)
Etanercept + Sulfasalazine	2 (1.2)	1 (1.7)	0 (0.0)	1 (1.3)
Infliximab	18 (11.2)	5 (8.3)	2 (7.7)	11 (14.7)
- Combination	10 (6.2)	2 (3.3)	1 (3.8)	7 (9.3)
Infliximab + Methotrexate	6 (3.7)	0 (0.0)	1 (3.8)	5 (6.7)
Infliximab + Leflunomide	2 (1.2)	1 (1.7)	0 (0.0)	1 (1.3)
Infliximab + Sulfasalazine	2 (1.2)	1 (1.7)	0 (0.0)	1 (1.3)
- Unknown	1 (0.6)	0 (0.0)	1 (3.8)	0 (0.0)
Golimumab	12 (7.5)	7 (11.7)	2 (7.7)	3 (4.0)
- Combination	9 (5.6)	5 (8.3)	1 (3.8)	3 (4.0)
Golimumab + Methotrexate	5 (3.1)	4 (6.7)	0 (0.0)	1 (1.3)
Golimumab + Leflunomide	4 (2.5)	1 (1.7)	1 (3.8)	2 (2.7)
Certolizumab	9 (5.6)	3 (5.0)	2 (7.7)	4 (5.3)
- Combination	6 (3.7)	3 (5.0)	0 (0.0)	3 (4.0)
Certolizumab + Methotrexate	3 (1.9)	1 (1.7)	0 (0.0)	2 (2.7)
Certolizumab + Leflunomide	2 (1.2)	1 (1.7)	0 (0.0)	1 (1.3)
Certolizumab + Sulfasalazine	1 (0.6)	1 (1.7)	0 (0.0)	0 (0.0)

	Overall	SECU150	SECU300	IXE
Patients – n (%)	221 (100.0)	103 (100.0)	38 (100.0)	80 (100.0)
Ustekinumab	6 (3.7)	3 (5.0)	0 (0.0)	3 (4.0)
- Combination (Ustekinumab + Methotrexate)	1 (0.6)	0 (0.0)	0 (0.0)	1 (1.3)
Treatment in patients with tsDMARD as first agent – n (%)				
Apremilast	6 (3.7)	2 (3.3)	2 (7.7)	2 (2.7)
- Combination (Apremilast + Methotrexate)	2 (1.2)	0 (0.0)	2 (7.7)	0 (0.0)

PsA: Psoriatic arthritis, bDMARD: biologic Disease-Modifying Anti-Rheumatic Drug, tsDMARD: targeted synthetic Disease-Modifying Anti-Rheumatic Drug, SECU150: Secukinumab 150mg, SECU300: Secukinumab 300mg, IXE: Ixekizumab.

Figure 1 – Time to discontinuation of index treatments: Kaplan-Meier curve of SECU150, SECU300 and IXE



SECU150: Secukinumab 150mg, SECU300: Secukinumab 300mg, IXE: Ixekizumab.